William Blair initiated coverage of Dianthus (DNTH) with an Outperform rating. Dianthus is a clinical-stage biotech company developing DNTH103 for autoimmune neuromuscular indications, notes the analyst, who sees fair value of $47.57 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Dianthus Therapeutics: Promising Prospects in Autoimmune Complement Inhibitor Market with DNTH103 Advancements
- Optimistic Buy Rating for Dianthus Therapeutics Amidst Promising C1s Inhibition Developments
- Buy Rating for Dianthus Therapeutics: Promising Growth Potential of DNTH103 in Neuromuscular Disease Treatment
- Dianthus Therapeutics Announces Board Changes and Elections
- Buy Rating Affirmed for Dianthus Therapeutics: Promising Clinical Potential of DNTH103 in CIDP Treatment